Fig 2: Increased AKIP1 expression is associated with advanced clinicopathological features. Association between AKIP1 IHC score and (A) myometrial invasion status, (B) cervical invasion status, (C) lymphovascular invasion status and (D) FIGO stage in patients with endometrial carcinoma. Association between AKIP1 mRNA expression and (E) myometrial invasion status, (F) cervical invasion status, (G) lymphovascular invasion status and (H) FIGO stage in patients with endometrial carcinoma. AKIP1, A-kinase-interacting protein 1; IHC, immunohistochemistry; FIGO, International Federation of Gynecology and Obstetrics.

Fig 3: Silencing of AKIP1 enhances Ishikawa cell chemosensitivity. Effect of AKIP1 siRNA on relative cell viability under different concentrations of (A) cisplatin and (B) paclitaxel treatment in Ishikawa cells (AKIP1 siRNA group vs. NC siRNA group). Comparison of IC50 value of (C) cisplatin and (D) paclitaxel in Ishikawa cells transfected with NC siRNA and AKIP siRNA (data are presented as mean ± SD). AKIP1, A-kinase-interacting protein 1; NC, negative control; siRNA, small interfering RNA; IC50, half maximal inhibitory concentration; SD, standard deviation.

Fig 4: AKIP1 expression is increased in tumor tissue compared with that in adjacent tissue in patients with endometrial cancer. (A) Representative images of AKIP1 staining in adjacent and tumor tissues (magnification, ×200). (B) Comparison of AKIP1 IHC score between adjacent and tumor tissues [data are presented as median (IQR)]. (C) ROC curve analysis of AKIP1 IHC score in differentiating tumor tissue from adjacent tissue. (D) Comparison of AKIP1 mRNA expression between adjacent and tumor tissues [data are presented as median (IQR)]. (E) ROC curve analysis of AKIP1 mRNA expression in differentiating tumor tissue from adjacent tissue. AKIP1, A-kinase-interacting protein 1; IHC, immunohistochemistry; ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval; IQR, interquartile range